Brief: Acurx Announces Positive Phase 2B Results Showing 100% Of Patients Who Had Clinical Cure With Ibezapolstat Also Had Sustained Clinical Cure
11/12/2023 12:22
Dec 11 (Reuters) - Acurx Pharmaceuticals Inc ACXP.O :
* ACURX ANNOUNCES POSITIVE PHASE 2B RESULTS SHOWING 100% OF
PATIENTS WHO HAD CLINICAL CURE WITH IBEZAPOLSTAT ALSO HAD
SUSTAINED CLINICAL CURE
* ACURX PHARMACEUTICALS: FURTHER ANALYSES WILL BE
FORTHCOMING Q1
2024, AS DATA BECOME AVAILABLE, REGARDING OTHER ENDPOINTS, FROM
PHASE 2B TRIAL
Source text for Eikon: ID:nPn5FgBWPa
Further company coverage: ACXP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Acurx Pharmaceuticals
See all newsBrief: Acurx Pharmaceuticals Receives FDA Conditional Acceptance
Acurx Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Acurx Pharmaceuticals Q2 loss widens on higher R&D costs
Acurx Pharmaceuticals Inc expected to post a loss of 38 cents a share - Earnings Preview
Brief: FDA Provides Further Regulatory Guidance To Acurx Pharmaceuticals For The Ibezapolstat Clinical Development Program